Wall Street Zen Upgrades Precigen (NASDAQ:PGEN) to Strong-Buy

Precigen (NASDAQ:PGEN) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

Other equities analysts also recently issued reports about the stock. Citizens Jmp increased their price objective on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Citigroup restated an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Zacks Research upgraded Precigen from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 5th. HC Wainwright increased their price target on Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.50.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $7.23 on Friday. The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.89 and a current ratio of 4.58. The company has a 50 day simple moving average of $5.23 and a two-hundred day simple moving average of $4.50. Precigen has a fifty-two week low of $1.70 and a fifty-two week high of $7.26. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of -6.95 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The firm had revenue of $54.98 million for the quarter, compared to analysts’ expectations of $27.98 million. The company’s revenue for the quarter was up 6322.7% compared to the same quarter last year. Analysts expect that Precigen will post 0.05 EPS for the current fiscal year.

Insider Buying and Selling at Precigen

In other news, CFO Harry Jr. Thomasian sold 171,429 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $5.53, for a total value of $948,002.37. Following the completion of the sale, the chief financial officer owned 354,535 shares of the company’s stock, valued at $1,960,578.55. This represents a 32.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Donald P. Lehr sold 29,131 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total transaction of $127,011.16. Following the completion of the sale, the insider directly owned 755,461 shares of the company’s stock, valued at $3,293,809.96. The trade was a 3.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 989,239 shares of company stock valued at $5,472,960. Insiders own 41.40% of the company’s stock.

Hedge Funds Weigh In On Precigen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Alpine Woods Capital Investors LLC acquired a new stake in Precigen in the 2nd quarter valued at $1,309,000. BlackRock Inc. purchased a new stake in shares of Precigen in the second quarter worth about $97,737,000. Deutsche Bank AG acquired a new stake in shares of Precigen in the second quarter valued at about $1,141,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Precigen in the second quarter valued at about $307,000. Finally, SCS Capital Management LLC purchased a new stake in shares of Precigen during the 2nd quarter valued at about $244,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen News Roundup

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.